section name header

Pronunciation ⬇

sir-OH-li-mus

Classifications ⬆ ⬇

Therapeutic Classification: Immunosuppressant agents

Indications ⬆ ⬇

High Alert


Action ⬆ ⬇

  • Inhibits mammalian target of rapamycin activation. Mechanism in treatment of angiofibroma associated with tuberous sclerosis unknown.
Therapeutic effects:
  • Reduction in size and redness of facial angiofibroma.

Pharmacokinetics ⬆ ⬇

Absorption: Minimally absorbed into systemic circulation.

Distribution: Not distributed to tissues.

Metabolism/Excretion: Unknown.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
Topicalunknownunknownunknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Hyftor

Code ⬆

NDC Code